Ortiz-Prado Esteban, Vasconez-Gonzalez Jorge, Izquierdo-Condoy Juan S, Suárez-Sangucho Isaac A, Prieto-Marín José Guillermo, Villarreal-Burbano Karen Bereniss, Barriga-Collantes Mateo Alejandro, Altamirano-Castillo John Alexander, Borja-Mendoza Domenic Anahi, Pazmiño-Almeida Jean Carlo, Cadena-Padilla María Paz
One Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
Front Nutr. 2025 Jun 9;12:1579957. doi: 10.3389/fnut.2025.1579957. eCollection 2025.
Vitamin D₃ (cholecalciferol) is a fat-soluble secosteroid with essential roles in calcium-phosphorus metabolism, bone health, and an expanding range of extraskeletal processes. Upon synthesis in the skin via ultraviolet B exposure or ingestion from dietary sources, cholecalciferol is hydroxylated in the liver and kidneys to form its active metabolite, calcitriol (1,25-dihydroxyvitamin D), which exerts pleiotropic effects through vitamin D receptor (VDR)-mediated genomic and non-genomic pathways. This narrative review synthesizes evidence on the systemic effects of high-dose cholecalciferol on bone health, metabolism, cardiovascular and immune function, and its emerging roles in neurological, gastrointestinal, reproductive, oncologic, and psychiatric disorders. High-dose vitamin D₃ has demonstrated benefits in specific populations, including improved bone mineral density, immune homeostasis, glycemic control, and reduced inflammation. In patients with chronic kidney disease, cystic fibrosis, and inflammatory bowel disease, targeted supplementation has been associated with clinical improvements. Preclinical models support calcitriol's antiproliferative and neuroprotective functions, and its synergistic effects with chemotherapy, although large-scale randomized controlled trials (RCTs) have yielded mixed or inconclusive results, particularly in cancer, cardiovascular events, and cognitive decline. Methodological variability-such as inconsistent dosing regimens, baseline vitamin D status, and heterogeneous populations-limits definitive conclusions. While vitamin D supplementation is generally safe within recommended limits, excessive intake may cause hypercalcemia or nephrolithiasis, emphasizing the need for personalized strategies. Food fortification and targeted screening remain underutilized yet cost-effective public health interventions. Overall, vitamin D₃ represents a promising but complex therapeutic agent, necessitating further rigorously designed clinical trials to establish evidence-based guidelines for its use in diverse pathological conditions.
维生素D₃(胆钙化醇)是一种脂溶性类固醇,在钙磷代谢、骨骼健康以及越来越多的骨骼外生理过程中发挥着重要作用。通过皮肤暴露于紫外线B或从饮食来源摄入后,胆钙化醇在肝脏和肾脏中发生羟基化,形成其活性代谢物骨化三醇(1,25 - 二羟基维生素D),它通过维生素D受体(VDR)介导的基因组和非基因组途径发挥多效性作用。这篇叙述性综述综合了关于高剂量胆钙化醇对骨骼健康、代谢、心血管和免疫功能的全身影响的证据,以及它在神经、胃肠、生殖、肿瘤和精神疾病中的新作用。高剂量维生素D₃已在特定人群中显示出益处,包括改善骨矿物质密度、免疫稳态、血糖控制和减轻炎症。在慢性肾病、囊性纤维化和炎症性肠病患者中,针对性补充维生素D₃与临床改善有关。临床前模型支持骨化三醇的抗增殖和神经保护功能,以及它与化疗的协同作用,尽管大规模随机对照试验(RCT)产生了混杂或不确定的结果,特别是在癌症、心血管事件和认知衰退方面。方法学上的差异,如给药方案不一致、基线维生素D状态和人群异质性,限制了得出明确结论。虽然在推荐剂量范围内补充维生素D一般是安全的,但过量摄入可能会导致高钙血症或肾结石,这强调了个性化策略的必要性。食品强化和针对性筛查仍是未得到充分利用但具有成本效益的公共卫生干预措施。总体而言,维生素D₃是一种有前景但复杂的治疗药物,需要进一步进行严格设计的临床试验,以建立在不同病理状况下使用它的循证指南。